학술논문
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
Document Type
article
Author
Cristina Valero; Mark Lee; Douglas Hoen; Kate Weiss; Daniel W. Kelly; Prasad S. Adusumilli; Paul K. Paik; George Plitas; Marc Ladanyi; Michael A. Postow; Charlotte E. Ariyan; Alexander N. Shoushtari; Vinod P. Balachandran; A. Ari Hakimi; Aimee M. Crago; Kara C. Long Roche; J. Joshua Smith; Ian Ganly; Richard J. Wong; Snehal G. Patel; Jatin P. Shah; Nancy Y. Lee; Nadeem Riaz; Jingming Wang; Ahmet Zehir; Michael F. Berger; Timothy A. Chan; Venkatraman E. Seshan; Luc G. T. Morris
Source
Nature Communications, Vol 12, Iss 1, Pp 1-9 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
There is an unmet clinical need for simple, accessible biomarkers to select patients who are more likely to respond to immune checkpoint therapy. Here the authors show that a lower neutrophil-to-lymphocyte ratio is associated with better overall and progressive-free survival, as well as higher rate of response, in a multi-cancer cohort of patients treated with immune checkpoint inhibitors.